Homepage > Company > Media > Pharma News > 2020 > Unichem Laboratories gets USFDA nod for drug to treat irregular heartbeat

Unichem Laboratories gets USFDA nod for drug to treat irregular heartbeat

Drug firm Unichem Laboratories NSE 1.46 % on Wednesday said it has received approval from the US health regulator for its Amiodarone tablets used to treat irregular heartbeat. The approved product is a generic version of Wyeth Pharmaceuticals Inc's Cordarone tablets.

The company has received abbreviated new drug application (ANDA) approval for its Amiodarone tablets, USP, 200 mg from the United States Food and Drug Administration (USFDA), Unichem Labs said in a filing to the BSE.

Unichem Labs said the product will be commercialised from its Ghaziabad, Uttar Pradesh, plant. Shares of Unichem Labs were trading 0.14 per cent higher at Rs 210.75 apiece on the BSE.

Jul 22, 2020

https://economictimes.indiatimes.com/

Read also

Phase 3 trials of treatment combo for hepatitis D expected in 2025

On the heels of positive Phase 2 clinical trial data, Vir Biotechnology is planning for the 2025 launch of a Phase 3 program, dubbed ECLIPSE, to test its treatment combination of tobevibart and elebsi...

Breakthrough Therapy Designation Market Is Booming Worldwide 2024-2032

The Breakthrough Therapy Designation market has witnessed significant growth over the past decade, driven by advancements in technology, shifting consumer preferences, and increasing investments from ...

Veeva Commercial Summit: Increased investment in medical affairs by pharma companies

Veeva’s VP of global medical, Christoph Bug, emphasises the importance of scientific exchange between clinical experts and pharmaceutical companies.

Remix

Remix Therapeutics to Present Preclinical Data Demonstrating Anti-Leukemic Activity of REM-422 in AML at the 66th American Society of Hematology Annual Meeting and Exposition (ASH)